1. Deletion of the Miz-1 POZ Domain Increases Efficacy of Cytarabine Treatment in T- and B-ALL/Lymphoma Mouse Models
- Author
-
Christian Kosan, Charles Vadnais, Jennifer Fraszczak, Charles Joly-Beauparlant, René Winkler, Julie A. Ross, Tarik Möröy, Marissa Rashkovan, and Arnaud Droit
- Subjects
0301 basic medicine ,Antimetabolites, Antineoplastic ,Cancer Research ,DNA damage ,Ubiquitin-Protein Ligases ,Genes, myc ,Mice, Transgenic ,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma ,03 medical and health sciences ,0302 clinical medicine ,Protein Domains ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,Animals ,Medicine ,Transcription factor ,Transcriptional activity ,business.industry ,Cytarabine ,DNA replication ,medicine.disease ,Protein Inhibitors of Activated STAT ,3. Good health ,Lymphoma ,Gene Expression Regulation, Neoplastic ,Leukemia ,030104 developmental biology ,Oncology ,Apoptosis ,030220 oncology & carcinogenesis ,Cancer research ,Female ,Tumor Suppressor Protein p53 ,business ,medicine.drug - Abstract
Acute lymphoblastic leukemia (ALL) is an aggressive blood cancer that mainly affects children. Relapse rates are high and toxic chemotherapies that block DNA replication and induce DNA damage lead to health problems later in life, underlining the need for improved therapies. MYC is a transcription factor that is hyperactive in a large proportion of cancers including leukemia but is difficult to target in therapy. We show that ablation of the function of the BTB/POZ domain factor Zbtb17 (Miz-1), an important cofactor of c-Myc, significantly delayed T- and B-ALL/lymphoma in mice and interfered with the oncogenic transcriptional activity of c-Myc. Leukemic cells that still emerged in this system activated DNA replication pathways that could be targeted by current chemotherapeutic drugs such as cytarabine. Acute ablation of the Miz-1 POZ domain enhanced the effect of cytarabine treatment. The combined treatment was effective in both Eμ-Myc and Notch ICN-driven leukemia models and prolonged survival of tumor-bearing animals by accelerating apoptosis of leukemic cells. These observations suggest that targeting MIZ-1 could render current ALL chemotherapies more effective, with a better outcome for patients. Significance: Ablation of the POZ domain of Miz-1 perturbs its interaction with c-MYC and delays the generation of T- and B-cell leukemias and lymphomas.
- Published
- 2019
- Full Text
- View/download PDF